RVT-1201 A Phase 2a, Double-Blind Placebo-Controlled Multicenter Study to Assess the Safety tolerability pharmacokinetics and pharmacodynamic effects of RVT-1201 in Patients with PAH
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Altavant Sciences, Inc.
Start Date
June 24, 2019
End Date
May 31, 2021
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Altavant Sciences, Inc.
Start Date
June 24, 2019
End Date
May 31, 2021